Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL Y821F |
| Therapy | Bemcentinib + Cetuximab |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL Y821F | head and neck squamous cell carcinoma | no benefit | Bemcentinib + Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, combining Bemcentinib (BGB-324) with Erbitux (cetuximab) treatment inhibited proliferation of head and neck squamous cell carcinoma cells expressing AXL Y821F, but did not enhance inhibition compared to cells treated with Erbitux (cetuximab) alone in culture (PMID: 32439698). | 32439698 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32439698) | AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. | Full reference... |